A case of rhabdomyolysis and thromboembolic event secondary to fibrate monotherapy

Acta Cardiologica

Volumn 63, Issue 4, 2008, Pages 515-517

  Yildiz, Abdulkadir ^a   Gucuk, Esra ^a   Cay, Serkan ^a,b  

^a Turkiye Yuksek Ihtisas Teaching and Research Hospital   (Turkey)

^b NONE   (Turkey)

Author keywords

Fibrate; Rhabdomyolysis; Thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; BICARBONATE; BISOPROLOL; D DIMER; DOXAZOSIN; FENOFIBRATE; FUROSEMIDE; HEPARIN; ISOTONIC SOLUTION; PROTEIN C; PROTEIN S; TRIACYLGLYCEROL;

ACUTE KIDNEY FAILURE; AGED; ANAMNESIS; ARTERY THROMBOSIS; ARTICLE; BLOOD GAS ANALYSIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DOPPLER ECHOGRAPHY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FATIGUE; HUMAN; HYPERKALEMIA; HYPERSENSITIVITY REACTION; HYPERTENSION; LUNG ANGIOGRAPHY; MALE; METABOLIC ACIDOSIS; MUSCLE WEAKNESS; MYALGIA; PH MEASUREMENT; PLEURAL PAIN; PROTEIN BLOOD LEVEL; RHABDOMYOLYSIS; SIDE EFFECT; SINUS TACHYCARDIA; THROMBOEMBOLISM; TRIACYLGLYCEROL BLOOD LEVEL; URINE COLOR;

AGED; ANTILIPEMIC AGENTS; CLOFIBRIC ACID; HUMANS; KIDNEY FAILURE, ACUTE; MALE; RHABDOMYOLYSIS; RISK FACTORS; THROMBOEMBOLISM;

EID: 52249091965     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.63.4.2033052     Document Type: Article

References (10)

1. Kursat S, Alici T, Colak HB. A case of rhabdomyolysis induced acute renal failure secondary to statin-fibrate-derivative combination and occult hypothyroidism. Clin Nephrol 2005; 64: 391-3.
2. Ireland JH, Eggert CH, Arendt CJ, Williams AW. Rhabdomyolysis with cardiac involvement and acute renal failure in a patient taking rosuvastatin and fenofibrate. Ann Intern Med 2005; 142: 949-50.
3. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005; 95:120-2.
4. Alsheikh-Ali AA, Kuvin JT, Karas RH. Risk of adverse events with fibrates. Am J Cardiol 2004; 94: 935-8.
5. Barker BJ, Goodenough RR, Falko JM. Fenofibrate monotherapy induced rhabdomyolysis. Diabetes Care 2003; 26: 2482-3.
6. Clouâtre Y, Leblanc M, Ouimet D, Pichette V. Fenofibrate-induced rhabdomyolysis in two dialysis patients with hypothyroidism. Nephrol Dial Transplant 1999; 14: 1047-8.
7. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001; 35: 908-17.
8. Prueksaritanont T, Zhao JJ, Ma B, Roadcap BA, Tang C, Qiu Y, Liu L, Lin JH, Pearson PG, Baillie TA. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002; 301: 1042-51.
9. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-61.
10. Maghzal GJ, Brennan SO, George PM. The sialic acid content of fibrinogen decreases during pregnancy and increases in response to fibrate therapy. Thromb Res 2005; 115: 293-9.